Perspective | Why this stage of the pandemic makes us so anxious
Since June, the United States has taken significant steps backward in fighting the coronavirus, leading to “pandemic flux syndrome.”
Related Articles
Progressive Supranuclear Palsy – Symptoms, Causes, Treatment | NORD
Learn about Progressive Supranuclear Palsy, including symptoms, causes, and treatments. If you or a loved one is affected by this condition, visit NORD to
How to find the person who can help you get ahead at work
The workplace is often presented as a meritocracy, where you can succeed by putting your head down and working hard. Wall Street veteran Carla Harris…
Physician Disruptive Behavior Compromising Safe Care Delivery
The negative impact and management of disruptive behavior are discussed in the article by Monika Kumar, et al.
Top Lung Cancer News From 2023 and What’s in Store for 2024
With practice-changing data and new approaches, it was a big year in lung cancer. Devika Das, MD, and Charu Aggarwal, MD, MPH, discuss 2023’s key…
This commonly prescribed cancer drug was supposed to help save his life. Instead, it killed him
Anil (Monty) Kapoor died on Feb. 28 after being prescribed a cancer drug that was toxic to him. From left, brothers Dr. Vimal (Scott) Kapoor,…
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
State of Lung Cancer | Alabama
The American Lung Association’s LUNG FORCE “State of Lung Cancer” report shows how the toll of lung cancer varies by state. Look at the rates…
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.